Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oncotelic Therapeutics, Inc.MATN · Entity 7822 | Director | June 20, 2018 | June 22, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oncotelic Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.22 · Expires 2024-06-20 | Direct | 258,171 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 258,171 · Balance 258,171 F1: Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2: The Stock Options will vest in full on June 20, 2019, subject to Dr. Chaplin's continued service on the Board of Directors as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy.
F2: The Stock Options will vest in full on June 20, 2019, subject to Dr. Chaplin's continued service on the Board of Directors as of such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2018 Filed Jun 22, 2018 20:12 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantStock Option (Right to Buy) · Derivative | 258,171 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001209191-18-039167 · doc4.xml · derivative · entry 1 CHAPLIN DAVID · CIK 0001167232 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,171 Underlying: Common Stock · 258,171 shares Expires 2024-06-20 F1 · shares: Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the "Stock Options"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The Stock Options will vest in full on June 20, 2019, subject to Dr. Chaplin's continued service on the Board of Directors as of such date. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 22:01 UTC | Oncotelic Therapeutics, Inc. MATN · Entity 7822 | GrantEmployee Stock Option (Right to Buy) · Derivative | 262,500 | $0.38 Strike: $0.38 | $98,437.50 |
DisclosureSEC source: 0001209191-17-003700 · doc4.xml · derivative · entry 1 CHAPLIN DAVID · CIK 0001167232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2027-01-12 F1 · shares: Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer. F2 · derivative.exercise_date: The Options will vest in forty-eight equal monthly installments beginning one month after the grant date. F1 · derivative.underlying_shares: Dr. Chaplin was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as Chief Scientific Officer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.